Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06034743
Other study ID # D6970C00002
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 22, 2023
Est. completion date October 13, 2025

Study information

Verified date May 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).


Recruitment information / eligibility

Status Recruiting
Enrollment 720
Est. completion date October 13, 2025
Est. primary completion date October 13, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria: - Male or female participants must be = 18 years old - Mean sitting systolic blood pressure on automated office blood pressure measurement = 140 mmHg and < 170 mmHg at Screening - Fulfil at least 1 of the following 2 criteria: 1. uHTN subpopulation: have a stable regimen of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator 2. rHTN subpopulation: have a stable regimen of = 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator - Estimated glomerular filtration rate = 45 mL/min/1.73m2 at Screening - Serum potassium (K+) level = 3.5 and < 5.0 mmol/L at Screening - Randomisation Criterion: - Sitting systolic blood pressure on attended automated office blood pressure measurement of = 135 mmHg at the Baseline Visit Exclusion Criteria: - Mean sitting systolic blood pressure on attended automated office blood pressure measurement = 170 mmHg - Mean seated diastolic blood pressure on attended automated office blood pressure measurement = 110 mmHg - Serum sodium level < 135 mmol/L at Screening - Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation - New York Heart Association functional heart failure class IV at Screening - Persistent atrial fibrillation

Study Design


Intervention

Drug:
Baxdrostat
Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: 1 mg per tablet for 1 mg baxdrostat Arm; 2 mg per tablet for 2 mg baxdrostat Arm.
Placebo
Placebo tablet matching baxdrostat, administered orally, once daily (QD).

Locations

Country Name City State
Argentina Research Site Buenos Aires
Argentina Research Site Caba
Argentina Research Site Caba
Argentina Research Site Cordoba
Argentina Research Site Córdoba
Argentina Research Site Mar del Plata
Argentina Research Site Mendoza
Argentina Research Site Rosario
Argentina Research Site San Miguel de Tucuman
Argentina Research Site San Nicolás
Argentina Research Site San Vicente
Australia Research Site Clayton
Australia Research Site Darlinghurst
Australia Research Site Epping
Australia Research Site Geelong
Australia Research Site Liverpool
Australia Research Site New Lambton Heights
Australia Research Site Perth
Australia Research Site Wollongong
Australia Research Site Woolloongabba
Austria Research Site Braunau am Inn
Austria Research Site St. Pölten
Austria Research Site Wien
Belgium Research Site Aalst
Belgium Research Site Genk
Belgium Research Site Gent
Belgium Research Site Leuven
Belgium Research Site Liège
Belgium Research Site Mons
Bulgaria Research Site Pleven
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Canada Research Site Cambridge Ontario
Canada Research Site Chicoutimi Quebec
Canada Research Site Edmonton Alberta
Canada Research Site Markham Ontario
Canada Research Site Newmarket Ontario
Canada Research Site North Vancouver British Columbia
Canada Research Site Ottawa Ontario
Canada Research Site St Jean sur Richelieu Quebec
Canada Research Site Toronto Ontario
Canada Research Site Waterloo Ontario
Czechia Research Site Benesov
Czechia Research Site Brandys nad Labem
Czechia Research Site Broumov
Czechia Research Site Louny
Czechia Research Site Ostrava
Czechia Research Site Pribram
Czechia Research Site Uherske Hradiste
Denmark Research Site Aarhus
Denmark Research Site Herning
Denmark Research Site Holbæk
France Research Site Bobigny
France Research Site Bordeaux
France Research Site Lille
France Research Site Paris
France Research Site Paris Cedex 14
France Research Site Poitiers
France Research Site Sr Priest En Jarez
France Research Site Toulon
France Research Site Toulouse
France Research Site Tours CEDEX
Germany Research Site Bad Homburg
Germany Research Site Bad Oeynhausen
Germany Research Site Berlin
Germany Research Site Berlin
Germany Research Site Dortmund
Germany Research Site Düsseldorf
Germany Research Site Elsterwerda
Germany Research Site Erfurt
Germany Research Site Erlangen
Germany Research Site Essen
Germany Research Site Frankfurt
Germany Research Site Frankfurt
Germany Research Site Frankfurt am Main
Germany Research Site Hannover
Germany Research Site Hannover
Germany Research Site Homburg
Germany Research Site Kaiserslautern
Germany Research Site Leipzig
Germany Research Site Lübeck
Germany Research Site Mainz
Germany Research Site Mannheim
Germany Research Site Marburg
Germany Research Site Regensburg
Germany Research Site Wermsdorf
Hungary Research Site Budapest
Hungary Research Site Kaposvár
Hungary Research Site Nyíregyháza
Hungary Research Site Szeged
India Research Site Delhi
India Research Site Delhi
India Research Site Guntur
India Research Site Hyderabad
India Research Site Jaipur
India Research Site Kanpur
India Research Site Kolkata
India Research Site Kolkata
India Research Site Kolkata
India Research Site Manipal
India Research Site Mysuru
India Research Site Mysuru
India Research Site New Delhi
India Research Site New Delhi
India Research Site Puducherry
India Research Site Pune
India Research Site Surat
Israel Research Site Ashdod
Israel Research Site Haifa
Israel Research Site petach Tikva
Israel Research Site Ramat Gan
Israel Research Site Rehovot
Italy Research Site Acquaviva delle Fonti
Italy Research Site Bologna
Italy Research Site Brescia
Italy Research Site Milano
Italy Research Site Milano
Italy Research Site Milano
Italy Research Site Pisa
Italy Research Site Roma
Italy Research Site Torino
Italy Research Site Udine
Japan Research Site Adachi-ku
Japan Research Site Chuo-ku
Japan Research Site Chuo-ku
Japan Research Site Chuo-ku
Japan Research Site Kanazawa-shi
Japan Research Site Koga-shi
Japan Research Site Kyoto-shi
Japan Research Site Nagasaki-shi
Japan Research Site Okayama-shi
Japan Research Site Osaka-shi
Japan Research Site Sapporo-shi
Japan Research Site Tsuchiura-shi
Japan Research Site Yufu-shi
Korea, Republic of Research Site Bucheon-si
Korea, Republic of Research Site Busan
Korea, Republic of Research Site Daejeon
Korea, Republic of Research Site Incheon
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Malaysia Research Site Kajang
Malaysia Research Site Kota Bharu
Malaysia Research Site Kuching
Malaysia Research Site Melaka
Malaysia Research Site Muar
Malaysia Research Site Sarawak Miri
Malaysia Research Site Seri Manjung
Netherlands Research Site Amsterdam
Netherlands Research Site Hoogeveen
Netherlands Research Site Nijmegen
Netherlands Research Site Utrecht
Poland Research Site Bialystok
Poland Research Site Bydgoszcz
Poland Research Site Chrzanów
Poland Research Site Gdansk
Poland Research Site Gdynia
Poland Research Site Kraków
Poland Research Site Lodz
Poland Research Site Poznan
Poland Research Site Warszawa
Poland Research Site Warszawa
Poland Research Site Warszawa
Slovakia Research Site Bratislava
Slovakia Research Site Brezno
Slovakia Research Site Kosice
Slovakia Research Site Moldava nad Bodvou
Slovakia Research Site Presov
Slovakia Research Site Rimavska Sobota
Slovakia Research Site Svidník
Slovakia Research Site Trnava
South Africa Research Site Cape Town
South Africa Research Site Centurion
South Africa Research Site Claremont
South Africa Research Site Durban
South Africa Research Site Kwadwesi
South Africa Research Site Somerset West
South Africa Research Site Worcester
Spain Research Site Barcelona
Spain Research Site Barcelona
Spain Research Site Ferrol
Spain Research Site Granada
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Majadahonda
Spain Research Site Oviedo
Spain Research Site Sevilla
Spain Research Site Terrassa
Sweden Research Site Göteborg
Sweden Research Site Stockholm
Sweden Research Site Uppsala
Taiwan Research Site Kaohsiung
Taiwan Research Site Kaohsiung
Taiwan Research Site Taichung
Taiwan Research Site Taichung
Taiwan Research Site Taipei
Taiwan Research Site Taipei
Taiwan Research Site Taipei City
Taiwan Research Site Yung Kang City
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Chiang Mai
Thailand Research Site Hat Yai
Thailand Research Site Muang
Thailand Research Site Muang
Thailand Research Site Pathumthani
Turkey Research Site Adana
Turkey Research Site Ankara
Turkey Research Site Bursa
Turkey Research Site Dinar
Turkey Research Site Istanbul
Turkey Research Site Izmir
Turkey Research Site Kütahya
Turkey Research Site Odunpazari
United Kingdom Research Site Bristol
United Kingdom Research Site Chesterfield
United Kingdom Research Site Dundee
United Kingdom Research Site Glasgow
United Kingdom Research Site London
United Kingdom Research Site Prescot
United Kingdom Research Site Stockport
United Kingdom Research Site Yate
United States Research Site Anaheim California
United States Research Site Atlanta Georgia
United States Research Site Augusta Georgia
United States Research Site Bethlehem Pennsylvania
United States Research Site Birmingham Alabama
United States Research Site Birmingham Alabama
United States Research Site Boston Massachusetts
United States Research Site Bronx New York
United States Research Site Brownsville Texas
United States Research Site Chapel Hill North Carolina
United States Research Site Chicago Illinois
United States Research Site Clearwater Florida
United States Research Site Clearwater Florida
United States Research Site Columbia Missouri
United States Research Site Corpus Christi Texas
United States Research Site Dallas Texas
United States Research Site Decatur Georgia
United States Research Site Detroit Michigan
United States Research Site East Providence Rhode Island
United States Research Site Fresno California
United States Research Site Grants Pass Oregon
United States Research Site Hinsdale Illinois
United States Research Site Houston Texas
United States Research Site Jacksonville Florida
United States Research Site Kansas City Missouri
United States Research Site Kansas City Missouri
United States Research Site Kansas City Missouri
United States Research Site Langhorne Pennsylvania
United States Research Site Lexington Kentucky
United States Research Site Lincoln California
United States Research Site Little Rock Arkansas
United States Research Site Madison Wisconsin
United States Research Site Manassas Virginia
United States Research Site Memphis Tennessee
United States Research Site Milwaukee Wisconsin
United States Research Site Munster Indiana
United States Research Site New Bern North Carolina
United States Research Site New Haven Connecticut
United States Research Site Olive Branch Mississippi
United States Research Site Orange California
United States Research Site Port Orange Florida
United States Research Site Rancho Cucamonga California
United States Research Site Rochester Minnesota
United States Research Site Rochester New York
United States Research Site Rosedale New York
United States Research Site Saraland Alabama
United States Research Site Scottsdale Arizona
United States Research Site Springfield Illinois
United States Research Site Stanford California
United States Research Site Suffolk Virginia
United States Research Site Sugar Land Texas
United States Research Site Sun City West Arizona
United States Research Site Surprise Arizona
United States Research Site Toledo Ohio
United States Research Site Troy Michigan
Vietnam Research Site Da Nang
Vietnam Research Site Ha Noi
Vietnam Research Site Hanoi
Vietnam Research Site Ho Chi Minh
Vietnam Research Site Ho Chi Minh
Vietnam Research Site Hochiminh city

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Australia,  Austria,  Belgium,  Bulgaria,  Canada,  Czechia,  Denmark,  France,  Germany,  Hungary,  India,  Israel,  Italy,  Japan,  Korea, Republic of,  Malaysia,  Netherlands,  Poland,  Slovakia,  South Africa,  Spain,  Sweden,  Taiwan,  Thailand,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of participants with adverse events (AEs) To assess the safety and tolerability of baxdrostat versus placebo. Occurrence of adverse events (AE), including serious adverse events (SAEs), adverse events leading to treatment discontinuation (DAE) and adverse events of special interest (AESI). Up to Week 54
Primary Change from baseline in seated systolic blood pressure for 2 mg baxdrostat To assess the effect of 2 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12 At Week 12
Primary Change from baseline in seated systolic blood pressure for 1 mg baxdrostat To assess the effect of 1 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12 At Week 12
Secondary Change from randomised withdrawal baseline (Week 24) in seated systolic blood pressure (SBP) for 2 mg baxdrostat To assess the effect of 2 mg baxdrostat vs placebo on seated systolic blood pressure (SBP) at 8 weeks after randomised withdrawal At Week 32
Secondary Change from baseline in seated SBP for 2 mg baxdrostat To assess the effect of 2 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation At Week 12
Secondary Change from baseline in seated diastolic blood pressure (DBP) for 2 mg baxdrostat To assess the effect of 2 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12 At Week 12
Secondary Achieving seated SBP < 130 mmHg for 2 mg baxdrostat To assess the effect of 2 mg baxdrostat vs placebo on achieving seated SBP < 130 mmHg at Week 12 At Week 12
Secondary Change from baseline in seated SBP for 1 mg baxdrostat To assess the effect of 1 mg baxdrostat vs placebo on seated SBP at Week 12 in the rHTN subpopulation At Week 12
Secondary Change from baseline in seated DBP for 1 mg baxdrostat To assess the effect of 1 mg baxdrostat vs placebo on seated DBP at Week 12 At Week 12
Secondary Achieving seated SBP < 130 mmHg for 1 mg baxdrostat To assess the effect of 1 mg baxdrostat vs placebo on achieving seated SBP < 130 mmHg at Week 12 At Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT05545059 - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Phase 3
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05426707 - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension N/A
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Active, not recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Terminated NCT02295683 - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4
Recruiting NCT04637152 - Sacubitril/Valsartan in Resistant Hypertension Phase 2